Table 4 In vitro antifungal susceptibilities of 43 clinical C. africana isolates as determined by the Clinical and Laboratory Standards Institute (CLSI) method
From: Multilocus sequence typing analysis of Candida africana from vulvovaginal candidiasis
Candida species | AmB | FLU | NYS | TEB | AFG | CFG | MFG | |
|---|---|---|---|---|---|---|---|---|
C. africana DST 182 (14) | Range GM MIC90 | 0.030–0.250 0.052 0.125 | 0.250–8.000 1.166 4.000 | 0.125–4.000 0.734 4.000 | 8.000–256.000 47.031 128.000 | 0.008–0.030 0.015 0.015 | 0.125–0.500 0.396 0.500 | 0.015–0.500 0.056 0.125 |
C. africana DST 782 (22) | Range GM MIC90 | 0.030–1.000 0.064 0.250 | 0.125–2.000 0.567 2.000 | 0.125–8.000 0.707 4.000 | 4.000–256.000 21.008 128.000 | 0.008–2.000 0.013 0.015 | 0.005–0.500 0.208 0.500 | 0.015–0.125 0.026 0.125 |
C. africana DST 3142 (7) | Range GM MIC90 | 0.030–0.125 0.061 0.125 | 0.125–2.000 0.410 1.000 | 0.250–4.000 0.371 0.250 | 4.000–128.000 28.983 64.000 | 0.008–0.015 0.010 0.015 | 0.005–0.500 0.192 0.500 | 0.015–0.125 0.030 0.125 |
Sub-total (43) | Range GM MIC90 | 0.030–1.000 0.060 0.125 | 0.125–8.000 0.633 2.000 | 0.125–8.000 0.633 4.000 | 4.000–256.000 26.979 128.000 | 0.008–2.000 0.013 0.015 | 0.005–0.500 0.239 0.500 | 0.015–0.500 0.032 0.125 |
C. albicans ATCC90028 (5) | Range GM MIC90 | 1.000 0.375 1.000 | 0.500–1.000 0.250 1.000 | 0.250–0.500 0.435 0.500 | 64.000–256.000 190.74 256.00 | 0.008–0.015 0.009 0.015 | 0.250 0.250 0.250 | 0.008–0.015 0.009 0.015 |